A Study to Evaluate Efficacy and Safety of GSK3858279 in Diabetic Peripheral Neuropathic Pain
Public ClinicalTrials.gov record NCT05838755. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multicenter Randomized, Double-blind, Placebo-controlled Phase 2 Study to Evaluate Efficacy, Safety, Tolerability, Pharmacokinetics and Target Engagement of GSK3858279 in Adult Participants With Chronic Diabetic Peripheral Neuropathic Pain (DPNP) /NEPTUNE-17
Study identification
- NCT ID
- NCT05838755
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- GlaxoSmithKline
- Industry
- Enrollment
- 147 participants
Conditions and interventions
Conditions
Interventions
- GSK3858279 Drug
- Placebo Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years to 75 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 19, 2023
- Primary completion
- Oct 13, 2024
- Completion
- Feb 16, 2025
- Last update posted
- Nov 20, 2025
2023 – 2025
United States locations
- U.S. sites
- 19
- U.S. states
- 12
- U.S. cities
- 18
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| GSK Investigational Site | Anniston | Alabama | 36207 | — |
| GSK Investigational Site | Surprise | Arizona | 85378 | — |
| GSK Investigational Site | Cerritos | California | 90703 | — |
| GSK Investigational Site | Lomita | California | 90717 | — |
| GSK Investigational Site | Largo | Florida | 33777 | — |
| GSK Investigational Site | Miami | Florida | 33135 | — |
| GSK Investigational Site | Miami | Florida | 33175 | — |
| GSK Investigational Site | West Palm Beach | Florida | 33401 | — |
| GSK Investigational Site | Decatur | Georgia | 30030 | — |
| GSK Investigational Site | Chicago | Illinois | 60611 | — |
| GSK Investigational Site | Waltham | Massachusetts | 02451 | — |
| GSK Investigational Site | Williamsville | New York | 14221 | — |
| GSK Investigational Site | Huntersville | North Carolina | 28078 | — |
| GSK Investigational Site | Lancaster | South Carolina | 29720 | — |
| GSK Investigational Site | Cypress | Texas | 77429 | — |
| GSK Investigational Site | DeSoto | Texas | 75154 | — |
| GSK Investigational Site | Houston | Texas | 77030 | — |
| GSK Investigational Site | McAllen | Texas | 78501 | — |
| GSK Investigational Site | Bellevue | Washington | 98007 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 62 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05838755, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 20, 2025 · Synced Jun 26, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05838755 live on ClinicalTrials.gov.